Literature DB >> 9259018

Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models.

K E Stevens1, K D Wear.   

Abstract

Rapid habituation of the evoked response to repeated auditory stimuli is a physiological manifestation of sensory gating mechanisms that are disturbed in human psychoses. Similar deficits are found in two animal models: fimbria-fornix lesioned Sprague-Dawley rats and DBA/2 mice, an inbred strain with decreased numbers of hippocampal alpha 7 nicotinic receptors. In response to paired auditory stimuli, the hippocampal evoked response of outbred, unlesioned animals is larger to the first than to the second stimulus. Both fimbria-fornix lesioned rats and DBA/2 mice have decreased response to the first stimulus but no further suppression of response to the second stimulus. Parenteral administration of (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT418), a newly developed nicotinic agonist, was found to normalize hippocampal auditory evoked responses in both models. The response to the first stimulus was increased, and the response to the second stimulus was suppressed relative to the first. The magnitude and time course of effect were similar to those observed with a 10-fold greater dose of nicotine. Both nicotine and ABT418 were ineffective when a second dose was administered 1 h later, suggesting that both compounds may desensitize the receptor mechanism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259018     DOI: 10.1016/s0091-3057(96)00466-2

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  44 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

2.  Comparison of the performance of DBA/2 and C57BL/6 mice in transitive inference and foreground and background contextual fear conditioning.

Authors:  Jessica M André; Kristy A Cordero; Thomas J Gould
Journal:  Behav Neurosci       Date:  2012-02-06       Impact factor: 1.912

Review 3.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

4.  Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.

Authors:  R Paylor; M Nguyen; J N Crawley; J Patrick; A Beaudet; A Orr-Urtreger
Journal:  Learn Mem       Date:  1998 Sep-Oct       Impact factor: 2.460

5.  Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice.

Authors:  Karen E Stevens; Brandon Cornejo; Catherine E Adams; Lijun Zheng; Joan Yonchek; Keith L Hoffman; Uwe Christians; William R Kem
Journal:  Brain Res       Date:  2010-07-03       Impact factor: 3.252

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 7.  Natural genetic variability of the neuronal nicotinic acetylcholine receptor subunit genes in mice: Consequences and confounds.

Authors:  Jennifer A Wilking; Jerry A Stitzel
Journal:  Neuropharmacology       Date:  2014-12-09       Impact factor: 5.250

Review 8.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

9.  Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.

Authors:  Karen E Stevens; Kevin S Choo; Jerry A Stitzel; Michael J Marks; Catherine E Adams
Journal:  Brain Res       Date:  2014-01-23       Impact factor: 3.252

10.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.